##  [Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants](/us-en/news/media-releases/novartis-canakinumab-acz885-reduced-cardiovascular-risk-25-subgroup-cantos-phase-iii-trial-participants-0 "Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants") 

  Nov 13, 2017